



Update Summary

Entity name

ATOMO DIAGNOSTICS LIMITED

Announcement Type

Update to previous announcement

Date of this announcement

28/7/2023

Reason for update to a previous announcement

To advise proposed director participation in the SPP announced on 13 July 2023
--

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

ATOMO DIAGNOSTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ABN

Registration Number

37142925684

1.3 ASX issuer code

AT1

1.4 The announcement is☒ Update/amendment to previous announcement**1.4a Reason for update to a previous announcement**

To advise proposed director participation in the SPP announced on 13 July 2023

1.4b Date of previous announcement to this update

13/7/2023

1.5 Date of this announcement

28/7/2023

1.6 The Proposed issue is:☒ An offer of +securities under a +securities purchase plan

Part 4 - Details of proposed offer under securities purchase plan

Part 4A - Conditions

4A.1 Do any external approvals need to be obtained or other conditions satisfied before the offer of +securities under the +securities purchase plan issue can proceed on an unconditional basis?

☒ Yes

4A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	15/9/2023	<input checked="" type="checkbox"/> Estimated	

Comments

AT1 has applied to ASX for a LR 7.1 waiver to permit the issue of SPP Shares without shareholder approval. It is proposed that AT1's Chair John Keith will apply for AUD15,000 worth of SPP Shares based on a SPP price of 3.6c. AT1 has also applied for a LR 10.11 waiver to permit the participation of directors and their associates in the SPP. In the event that the waivers are not granted, shareholder approval will be sought at an EGM.



Part 4B - Offer details

Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued

ASX +security code and description

AT1 : ORDINARY FULLY PAID

Will the proposed issue of this +security include an offer of attaching +securities?

☒ No

Details of +securities proposed to be issued

ASX +security code and description

AT1 : ORDINARY FULLY PAID

Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted

76,388,888

Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)?

☒ No

Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)?

☒ No

Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)?

☒ Yes

Is the minimum acceptance unit based or dollar based?

☒ Dollar based (\$)

Please enter the minimum acceptance value

\$ 1,000

Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)?

☒ Yes

Is the maximum acceptance unit based or dollar based?

☒ Dollar based (\$)

Please enter the maximum acceptance value

\$ 30,000



Describe all the applicable parcels available for this offer in number of securities or dollar value

\$1,000, \$2,500, \$7,500, \$10,000, \$15,000, \$20,000, \$30,000

Offer price details

Has the offer price been determined?

☒ Yes

In what currency will the offer be made?

AUD - Australian Dollar

What is the offer price per +security?

AUD 0.03600

Oversubscription & Scale back details

Will a scale back be applied if the offer is over-subscribed?

☒ Yes

Describe the scale back arrangements

Applications may be scaled back at the absolute discretion of the Company.

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

☒ Yes

Part 4C - Timetable

4C.1 Date of announcement of +security purchase plan

13/7/2023

4C.2 +Record date

12/7/2023

4C.3 Date on which offer documents will be made available to investors

18/7/2023

4C.4 Offer open date

18/7/2023

4C.5 Offer closing date

1/8/2023

4C.7 +Issue date and last day for entity to announce results of +security purchase plan offer

8/8/2023



Part 4D - Listing Rule requirements

4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements?

☒ No

4D.1a Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

☒ Yes

4D.1a (i) How many +securities are proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

All of the new shares proposed to be issued under the SPP, including allotments to directors and their associates, subject to ASX granting a waiver of LR 7.1 and LR 10.11

4D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

☒ No

Part 4E - Fees and expenses

4E.1 Will there be a lead manager or broker to the proposed offer?

☒ Yes

4E.1a Who is the lead manager/broker?

Bell Potter

4E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

The lead manager's fees comprise 6% of the funds raised under the SPP offer, with the exception of funds received from GZ Family Office.

4E.2 Is the proposed offer to be underwritten?

☒ No

4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?

☒ No

4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer



Part 4F - Further Information

4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

To fund hCG Pregnancy Test sales & marketing (ANZ/US); Iron Deficiency Test registration & commercial activity (ANZ/UK and Europe); POC Technology (OEM) business development; Product development (app, digital, Vitamin D); and working capital requirements.

4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?

☒ No

4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer

Shareholders who are not resident in Australia or New Zealand or the United Kingdom will not be able to participate in the SPP.

4F.3 URL on the entity's website where investors can download information about the proposed offer

<https://investors.atomodiagnostics.com/investor-centre/?page=asx-announcements>

4F.4 Any other information the entity wishes to provide about the proposed offer